ABSTRACT
INTRODUCTION
Prurigo nodularis (PN) of Hyde, also known as nodular prurigo, is a chronic skin disease of unknown etiology. It is characterized by an intensely pruritic papulonodular eruptions. The hyperkeratotic lesions tend to be symmetrical and occur over the extensor surfaces of the extremities. PN has been associated with a range of systemic conditions such as HIV/AIDS, depression, gastrointestinal disorders, hypothyroidism, and hematologic malignancies. In most cases, however, the etiology is unclear [1] [2] [3] [4] . First-line therapy for PN is comprised of topical antipruritics or corticosteroids, oral steroids, antihistamines, or certain antidepressants such as doxepin [5] . Additional commonly used treatments include phototherapy, capsaicin, cyclosporine, and methotrexate [3] . Recently, novel agents such as tumor necrosis factor (TNF) inhibitors alfacept and etanercept have also been prescribed [14] . Most of these therapies, however, are ineffective or only provide temporary relief. Thus, alternative treatments are needed for refractory cases.
In 1965, Sheskin was the first to report on the use of thalidomide to treat a patient with PN [6] . Thalidomide is a drug with numerous proposed mechanisms of action and effects, ranging from acting as a prostaglandin/ histamine antagonist to being an inhibitor of fibroblast growth factor and a immunomodulatory agent [7] . As an immunomodulatory drug, thalidomide functions to decrease TNF-a and inhibits polymorphonuclear leukocyte chemotaxis [7] . TNF-a induces pain by increasing the production of interleukin (IL)-1b and IL-6, which then increases the production of IL-8, a known mediator of sympathetic pain [8] [9] [10] .
More recently, thalidomide has also been shown to inhibit the peripheral vanilloid receptor 1 (TRVP1) channel, which is also involved in pain sensation [11] . Thalidomide became well known for its teratogenic effects leading to severe fetal malformations when taken by pregnant women before the third trimester [12] . This medication has other known side effects, which include peripheral neuropathy, somnolence, altered mood, thrombosis, and gastrointestinal symptoms.
Lenalidomide, a more potent analogue of thalidomide, has been most commonly used to treat multiple myeloma and myelodysplastic syndromes. Lenalidomide's molecular structure varies by one less carbonyl group but one additional amine compared to thalidomide [13] . This change confers a different toxicity profile and, as such, lenalidomide has a much lower frequency of peripheral neuropathy [14] . While some studies report the use of thalidomide and lenalidomide to be beneficial for the treatment of PN, their use in the management of PN remains controversial.
Thus, this review aims to explore and review the efficacy and safety of thalidomide and lenalidomide for the treatment of refractory PN. excluded. In addition, the SCOPUS Database was crosschecked, but no additional articles were found. As a result, a total of 18 articles were selected for inclusion in this review (Fig. 1 ). This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
METHODS

RESULTS
In the first reported case, Van de Broek et al. described a 57-year-old man with refractory PN admitted for an infection superimposed on nodules that had previously failed both topical and oral steroids as well as antihistamines [12] . Thalidomide 100 mg bis in die (BID) was used for 3 months and discontinued after resolution of the pruritis and lesions. No side effects were reported.
Andersen and Fogh retrospectively reviewed 42 subjects with PN treated with thalidomide [22] . Of these, 60% of patients showed clinical improvement, but 9.5% of patients showed no effect. The average daily dose was 100 mg, though a few patients received 50 mg due to gastrointestinal-related side effects. The mean duration of treatment was 105 weeks, and 59.5% of patients developed peripheral neuropathy ranging from 1 week to 7.5 years after initiation of treatment, prompting discontinuation of therapy at the time of symptom development. None of the subjects with neuropathy showed evidence of this adverse effect during follow-up. HIV-infected patients. They received thalidomide 100 mg per day and were randomized after 1 month to receive either 100 or 200 mg daily [4] . Doses were adjusted if adverse events appeared, thus daily dosing ranged from 33 to 200 mg. Eight patients (80%) continued the trial longer than 1 month, and all had a greater than 50% reduction in itch, while 7 (70%) had a greater than 50% reduction in lesions. Pruritic reduction occurred within 1-3 months of treatment, while decreases in erythema and nodule size occurred between 3-6 months. Three patients (30%) developed peripheral neuropathy; however, no association with neuropathy was found between treatment duration, daily dose, or cumulative dose.
Herranz et al. also treated a case of AIDS-associated PN in a 35-year-old white male with a CD4 count of 8 cells/mm 3 [2] .
Following a failed trial of topical corticosteroids and antihistamines, he was placed on thalidomide 100 mg daily for 6 weeks, upon which there was a drastic improvement of itching and lesions. The patient had a relapse of tuberculosis after 1 month of discontinuing thalidomide, which was postulated to have been due to the inhibitory effect of thalidomide on TNF-a. There were no other side effects reported.
Ferrandiz et al. conducted a prospective trial to evaluate combination therapy using thalidomide and ultraviolet-B (UVB) irradiation on four patients with PN [15] . Two patients had previously undergone a course of thalidomide but subsequently relapsed. Thalidomide was started at 100 mg daily and was discontinued once significant clinical improvement was achieved, ranging from 8 to 16 weeks. UVB phototherapy was then initiated for three sessions per week until complete clearance of the nodules was achieved, with a maximum of 70 exposures allowed. Most symptoms resolved after 6-12 UVB treatments, at which point thalidomide was also discontinued.
One patient developed temporary peripheral neuropathy and another developed nausea. The follow-up period ranged from 4-18 months, in which one patient experienced a relapse at 5 months, which was then successfully managed with 35 treatments of UVB irradiation.
Lenalidomide has also been used in patients experiencing toxicity with thalidomide. Kanavy et al. treated a 45-year-old black woman with a severe 10-year case of PN [14] . She was first treated with thalidomide 200 mg daily and had a dramatic improvement, but she developed neuropathy after 18 months and treatment was stopped. After thalidomide, she also was treated with oral naltrexone, minocycline, gabapentin, alafecept, and etanercept with no sucess [14] .
Thereafter, she was started on lenalidomide 5 mg a day and by the second week she noted a significant decrease in pruritus, sleep, and concentration ability. By the first month, she exhibited healing of nodules and disappearance of itching. Two attempts were made to taper her dose and both resulted in disease flare-ups, thus she was maintained on 5 mg/day for a total of 24 months. The patient remained in remission after 2 years. Liu 
TRENDS IN TREATMENT, DOSAGE, AND LENGTH
A total of 18 studies with 106 patients treated with thalidomide or lenalidomide for PN were reviewed (see Tables 1, 2 phototherapy and thalidomide at 100 mg daily for 2.5-5 months [15] . Excellent responses were achieved after an average of 3 months on thalidomide and 32 UVB courses [15] . One patient that was taking lenalidomide was kept on 5 mg for over 2 years, while the other took 10 mg daily for 3 months [11, 13] . For lenalidomide, treatment length was from 3 to over 24 months. Lenalidomide offered a relatively low toxicity treatment to patients who had toxicity to thalidomide.
TRENDS IN OUTCOMES
A total of 106 patients were included in this review, 76 (71.7%) of whom showed significant improvement in reduction of pruritus and disappearance of nodules [1, 2, 4, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
Only slight or mild improvement was seen in 11 (10.3%) patients [23, 25, 26] , while 15 (13.3%) patients showed no improvement at all [19, 23, 25, 26, 29] . Results were unable to be determined in four patients in one retrospective study [25] . Pruritus typically was the first to decrease with a noticeable clinical difference by 2-4 weeks followed by flattening of lesions and decreased excoriation which occurred at an average of 2 months. For patients who achieved complete or almost 
TRENDS IN ADVERSE EFFECTS
Peripheral neuropathy was the most common adverse effect. Overall, there were a reported 39 (36.8%) cases of peripheral neuropathy [1, 4, 15, 16, [18] [19] [20] [25] [26] [27] [28] not including the additional patients affected in Doherty and Hsu's study, as the exact amount was unable to be obtained [23] . Thalidomide-induced neuropathy developed after 1 week to 7.5 years of treatment [25] . In most cases, the peripheral neuropathy was reversible and took up several months to resolve. Some patients with HIV/ AIDS experienced peripheral neuropathy, but it was unclear if it was due to thalidomide or the HIV infection [1] . Clemmensen et al. had one patient who still experienced neuropathy over a year after discontinuation; however, it should be noted that the patient used the drug for 18 months [29] . Although no studies directly or extensively addressed the subject, there appears to be increased toxicity at higher doses of thalidomide [14, 20, 22, 26] . Sedation, gastrointestinal symptoms, and dizziness were the other most-often reported adverse effects.
Lenalidomide was used in two patients after they failed thalidomide therapy [14, 27] . The first patient discontinued thalidomide after developing peripheral neuropathy. She was then treated successfully with lenalidomide and had no recurrence of paresthesias [14] .
The other patient also developed tingling and decreased sensation with thalidomide; however, she eventually re-developed neuropathy after a trial of lenalidomide [27] . More studies are needed to determine the outcomes of thalidomide compared to lenalidomide, and [14, 15, 17, 22, 27] . Four achieved remission after a second course of completed therapy [15, 17, 22] , and one continued to have disease flare-ups with multiple attempts at tapering the dose, and thus was maintained on 5 mg/day of lenalidomide [14] . The last one had to stop treatment after courses of both thalidomide and lenalidomide due to neuropathy, and relapsed without further resolution [27] . 
CONCLUSION
